Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects

•Oleanolic acid (OA) improves hepatic insulin resistance in db/db mice.•OA inhibits mitochondrial oxidative stress via activation of Nrf2–GCLc signal.•OA suppresses hepatic lipid accumulation and inflammation. Insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM), which is closely re...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular and cellular endocrinology 2013-08, Vol.376 (1-2), p.70-80
Hauptverfasser: Wang, Xin, Liu, Rui, Zhang, Wei, Zhang, Xiaodi, Liao, Nai, Wang, Zhao, Li, Wenli, Qin, Xujun, Hai, Chunxu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 80
container_issue 1-2
container_start_page 70
container_title Molecular and cellular endocrinology
container_volume 376
creator Wang, Xin
Liu, Rui
Zhang, Wei
Zhang, Xiaodi
Liao, Nai
Wang, Zhao
Li, Wenli
Qin, Xujun
Hai, Chunxu
description •Oleanolic acid (OA) improves hepatic insulin resistance in db/db mice.•OA inhibits mitochondrial oxidative stress via activation of Nrf2–GCLc signal.•OA suppresses hepatic lipid accumulation and inflammation. Insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM), which is closely related to disorder of lipid metabolism. The study was designed to evaluate the effects of oleanolic acid (OA) on hepatic insulin resistance and underlying mechanisms in Lepdb/db obese diabetic mice. db/db Mice were administered with OA (20mg/kg/day, i.p.) for two weeks. OA reduced body weight, liver weight, and fat weight, and protected liver morphology and function. OA decreased fasting blood glucose, improved glucose and insulin tolerance, enhanced insulin signaling and inhibited gluconeogenesis. In livers, mitochondrial biogenesis, ultrastructure and function were influenced, accompanied by increased cellular and mitochondrial ROS production. OA inhibited all these changes, in which process Nrf2–GCLc mediated stabilization of mitochondrial glutathione pool may be involved. Moreover, OA decreased serum triglyceride, total cholesterol, LDL, HDL, and free fatty acids, increased serum HDL, and reduced hepatic lipid accumulation. Furthermore, inflammatory condition in db/db mice was improved by OA, as evidenced by decreased level of IL-1 β, IL-6, and TNFα in circulation and in liver. The evidence suggests that OA improves hepatic insulin resistance through inhibition of mitochondrial ROS, hypolipidemic and anti-inflammatory effects. The effectiveness of OA leads to interesting therapeutic perspectives.
doi_str_mv 10.1016/j.mce.2013.06.014
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1567091369</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0303720713002529</els_id><sourcerecordid>1567091369</sourcerecordid><originalsourceid>FETCH-LOGICAL-c476t-33d5ddada5a1bcdba10830f2fda1b33f5ab4b41f0619d61aef7e897e2b301f673</originalsourceid><addsrcrecordid>eNp9kE1v1DAQhi0EotvCD-ACOfZAwkycxIk4oaqUSpV6gJ6tiT2mXuULO7ti_z1etnDsaTTjZ16NHyHeIRQI2HzaFqPhogSUBTQFYPVCbLBVZd5CrV6KDUiQuSpBnYnzGLcAoOqyfS3OSqk6bKtqI-b7gWmaB28yMt5mflzCvOeYPfJCa5r6Ke4GP2WBo48rTYazvaeMptXPv71N9WP2eFhSwuItj8ecyf59zv3kBhpHWudwyNg5Nmt8I145GiK_faoX4uHr9Y-rb_nd_c3t1Ze73FSqWXMpbW0tWaoJe2N7QmgluNLZ1EvpauqrvkIHDXa2QWKnuO0Ul70EdI2SF-LylJu-82vHcdWjj4aHgSaed1Fj3SjoUDZdQvGEmjDHGNjpJfiRwkEj6KNnvdXJsz561tDo5DntvH-K3_Uj2_8b_8Qm4MMJcDRr-hl81A_fU0INgC3Kuk3E5xPBScPec9DReE5-rQ_JlLazf-aAP-f8mgs</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1567091369</pqid></control><display><type>article</type><title>Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Wang, Xin ; Liu, Rui ; Zhang, Wei ; Zhang, Xiaodi ; Liao, Nai ; Wang, Zhao ; Li, Wenli ; Qin, Xujun ; Hai, Chunxu</creator><creatorcontrib>Wang, Xin ; Liu, Rui ; Zhang, Wei ; Zhang, Xiaodi ; Liao, Nai ; Wang, Zhao ; Li, Wenli ; Qin, Xujun ; Hai, Chunxu</creatorcontrib><description>•Oleanolic acid (OA) improves hepatic insulin resistance in db/db mice.•OA inhibits mitochondrial oxidative stress via activation of Nrf2–GCLc signal.•OA suppresses hepatic lipid accumulation and inflammation. Insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM), which is closely related to disorder of lipid metabolism. The study was designed to evaluate the effects of oleanolic acid (OA) on hepatic insulin resistance and underlying mechanisms in Lepdb/db obese diabetic mice. db/db Mice were administered with OA (20mg/kg/day, i.p.) for two weeks. OA reduced body weight, liver weight, and fat weight, and protected liver morphology and function. OA decreased fasting blood glucose, improved glucose and insulin tolerance, enhanced insulin signaling and inhibited gluconeogenesis. In livers, mitochondrial biogenesis, ultrastructure and function were influenced, accompanied by increased cellular and mitochondrial ROS production. OA inhibited all these changes, in which process Nrf2–GCLc mediated stabilization of mitochondrial glutathione pool may be involved. Moreover, OA decreased serum triglyceride, total cholesterol, LDL, HDL, and free fatty acids, increased serum HDL, and reduced hepatic lipid accumulation. Furthermore, inflammatory condition in db/db mice was improved by OA, as evidenced by decreased level of IL-1 β, IL-6, and TNFα in circulation and in liver. The evidence suggests that OA improves hepatic insulin resistance through inhibition of mitochondrial ROS, hypolipidemic and anti-inflammatory effects. The effectiveness of OA leads to interesting therapeutic perspectives.</description><identifier>ISSN: 0303-7207</identifier><identifier>EISSN: 1872-8057</identifier><identifier>DOI: 10.1016/j.mce.2013.06.014</identifier><identifier>PMID: 23791844</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>Animals ; anti-inflammatory activity ; Anti-Inflammatory Agents, Non-Steroidal - pharmacology ; antioxidants ; Antioxidants - pharmacology ; biogenesis ; blood glucose ; Blood Glucose - metabolism ; blood serum ; body weight ; Body Weight - drug effects ; Cellular ; cholesterol ; Cytokines - antagonists &amp; inhibitors ; Cytokines - biosynthesis ; Diabetes Mellitus, Experimental - drug therapy ; Diabetes Mellitus, Experimental - metabolism ; Diabetes Mellitus, Type 2 - drug therapy ; Diabetes Mellitus, Type 2 - metabolism ; Dyslipidemia ; fasting ; free fatty acids ; Gluconeogenesis ; Glucose ; glutathione ; Hepatic insulin resistance ; high density lipoprotein ; Hypolipidemic Agents - pharmacology ; Inflammation ; Injections, Intraperitoneal ; Insulin ; Insulin - metabolism ; Insulin Resistance ; interleukin-1beta ; interleukin-6 ; lipid metabolism ; Lipid Metabolism - drug effects ; Liver ; Liver - drug effects ; Liver - metabolism ; low density lipoprotein ; Male ; Mice ; Mice, Transgenic ; Mitochondrial Turnover - drug effects ; Noise levels ; noninsulin-dependent diabetes mellitus ; Oleanolic acid ; Oleanolic Acid - pharmacology ; Organ Size - drug effects ; Reactive oxygen species ; Reactive Oxygen Species - antagonists &amp; inhibitors ; Serums ; triacylglycerols ; tumor necrosis factor-alpha ; ultrastructure ; Weight reduction</subject><ispartof>Molecular and cellular endocrinology, 2013-08, Vol.376 (1-2), p.70-80</ispartof><rights>2013 Elsevier Ireland Ltd</rights><rights>Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c476t-33d5ddada5a1bcdba10830f2fda1b33f5ab4b41f0619d61aef7e897e2b301f673</citedby><cites>FETCH-LOGICAL-c476t-33d5ddada5a1bcdba10830f2fda1b33f5ab4b41f0619d61aef7e897e2b301f673</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.mce.2013.06.014$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23791844$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Liu, Rui</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Zhang, Xiaodi</creatorcontrib><creatorcontrib>Liao, Nai</creatorcontrib><creatorcontrib>Wang, Zhao</creatorcontrib><creatorcontrib>Li, Wenli</creatorcontrib><creatorcontrib>Qin, Xujun</creatorcontrib><creatorcontrib>Hai, Chunxu</creatorcontrib><title>Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects</title><title>Molecular and cellular endocrinology</title><addtitle>Mol Cell Endocrinol</addtitle><description>•Oleanolic acid (OA) improves hepatic insulin resistance in db/db mice.•OA inhibits mitochondrial oxidative stress via activation of Nrf2–GCLc signal.•OA suppresses hepatic lipid accumulation and inflammation. Insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM), which is closely related to disorder of lipid metabolism. The study was designed to evaluate the effects of oleanolic acid (OA) on hepatic insulin resistance and underlying mechanisms in Lepdb/db obese diabetic mice. db/db Mice were administered with OA (20mg/kg/day, i.p.) for two weeks. OA reduced body weight, liver weight, and fat weight, and protected liver morphology and function. OA decreased fasting blood glucose, improved glucose and insulin tolerance, enhanced insulin signaling and inhibited gluconeogenesis. In livers, mitochondrial biogenesis, ultrastructure and function were influenced, accompanied by increased cellular and mitochondrial ROS production. OA inhibited all these changes, in which process Nrf2–GCLc mediated stabilization of mitochondrial glutathione pool may be involved. Moreover, OA decreased serum triglyceride, total cholesterol, LDL, HDL, and free fatty acids, increased serum HDL, and reduced hepatic lipid accumulation. Furthermore, inflammatory condition in db/db mice was improved by OA, as evidenced by decreased level of IL-1 β, IL-6, and TNFα in circulation and in liver. The evidence suggests that OA improves hepatic insulin resistance through inhibition of mitochondrial ROS, hypolipidemic and anti-inflammatory effects. The effectiveness of OA leads to interesting therapeutic perspectives.</description><subject>Animals</subject><subject>anti-inflammatory activity</subject><subject>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</subject><subject>antioxidants</subject><subject>Antioxidants - pharmacology</subject><subject>biogenesis</subject><subject>blood glucose</subject><subject>Blood Glucose - metabolism</subject><subject>blood serum</subject><subject>body weight</subject><subject>Body Weight - drug effects</subject><subject>Cellular</subject><subject>cholesterol</subject><subject>Cytokines - antagonists &amp; inhibitors</subject><subject>Cytokines - biosynthesis</subject><subject>Diabetes Mellitus, Experimental - drug therapy</subject><subject>Diabetes Mellitus, Experimental - metabolism</subject><subject>Diabetes Mellitus, Type 2 - drug therapy</subject><subject>Diabetes Mellitus, Type 2 - metabolism</subject><subject>Dyslipidemia</subject><subject>fasting</subject><subject>free fatty acids</subject><subject>Gluconeogenesis</subject><subject>Glucose</subject><subject>glutathione</subject><subject>Hepatic insulin resistance</subject><subject>high density lipoprotein</subject><subject>Hypolipidemic Agents - pharmacology</subject><subject>Inflammation</subject><subject>Injections, Intraperitoneal</subject><subject>Insulin</subject><subject>Insulin - metabolism</subject><subject>Insulin Resistance</subject><subject>interleukin-1beta</subject><subject>interleukin-6</subject><subject>lipid metabolism</subject><subject>Lipid Metabolism - drug effects</subject><subject>Liver</subject><subject>Liver - drug effects</subject><subject>Liver - metabolism</subject><subject>low density lipoprotein</subject><subject>Male</subject><subject>Mice</subject><subject>Mice, Transgenic</subject><subject>Mitochondrial Turnover - drug effects</subject><subject>Noise levels</subject><subject>noninsulin-dependent diabetes mellitus</subject><subject>Oleanolic acid</subject><subject>Oleanolic Acid - pharmacology</subject><subject>Organ Size - drug effects</subject><subject>Reactive oxygen species</subject><subject>Reactive Oxygen Species - antagonists &amp; inhibitors</subject><subject>Serums</subject><subject>triacylglycerols</subject><subject>tumor necrosis factor-alpha</subject><subject>ultrastructure</subject><subject>Weight reduction</subject><issn>0303-7207</issn><issn>1872-8057</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kE1v1DAQhi0EotvCD-ACOfZAwkycxIk4oaqUSpV6gJ6tiT2mXuULO7ti_z1etnDsaTTjZ16NHyHeIRQI2HzaFqPhogSUBTQFYPVCbLBVZd5CrV6KDUiQuSpBnYnzGLcAoOqyfS3OSqk6bKtqI-b7gWmaB28yMt5mflzCvOeYPfJCa5r6Ke4GP2WBo48rTYazvaeMptXPv71N9WP2eFhSwuItj8ecyf59zv3kBhpHWudwyNg5Nmt8I145GiK_faoX4uHr9Y-rb_nd_c3t1Ze73FSqWXMpbW0tWaoJe2N7QmgluNLZ1EvpauqrvkIHDXa2QWKnuO0Ul70EdI2SF-LylJu-82vHcdWjj4aHgSaed1Fj3SjoUDZdQvGEmjDHGNjpJfiRwkEj6KNnvdXJsz561tDo5DntvH-K3_Uj2_8b_8Qm4MMJcDRr-hl81A_fU0INgC3Kuk3E5xPBScPec9DReE5-rQ_JlLazf-aAP-f8mgs</recordid><startdate>20130825</startdate><enddate>20130825</enddate><creator>Wang, Xin</creator><creator>Liu, Rui</creator><creator>Zhang, Wei</creator><creator>Zhang, Xiaodi</creator><creator>Liao, Nai</creator><creator>Wang, Zhao</creator><creator>Li, Wenli</creator><creator>Qin, Xujun</creator><creator>Hai, Chunxu</creator><general>Elsevier Ireland Ltd</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7U5</scope><scope>8FD</scope><scope>L7M</scope></search><sort><creationdate>20130825</creationdate><title>Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects</title><author>Wang, Xin ; Liu, Rui ; Zhang, Wei ; Zhang, Xiaodi ; Liao, Nai ; Wang, Zhao ; Li, Wenli ; Qin, Xujun ; Hai, Chunxu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c476t-33d5ddada5a1bcdba10830f2fda1b33f5ab4b41f0619d61aef7e897e2b301f673</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Animals</topic><topic>anti-inflammatory activity</topic><topic>Anti-Inflammatory Agents, Non-Steroidal - pharmacology</topic><topic>antioxidants</topic><topic>Antioxidants - pharmacology</topic><topic>biogenesis</topic><topic>blood glucose</topic><topic>Blood Glucose - metabolism</topic><topic>blood serum</topic><topic>body weight</topic><topic>Body Weight - drug effects</topic><topic>Cellular</topic><topic>cholesterol</topic><topic>Cytokines - antagonists &amp; inhibitors</topic><topic>Cytokines - biosynthesis</topic><topic>Diabetes Mellitus, Experimental - drug therapy</topic><topic>Diabetes Mellitus, Experimental - metabolism</topic><topic>Diabetes Mellitus, Type 2 - drug therapy</topic><topic>Diabetes Mellitus, Type 2 - metabolism</topic><topic>Dyslipidemia</topic><topic>fasting</topic><topic>free fatty acids</topic><topic>Gluconeogenesis</topic><topic>Glucose</topic><topic>glutathione</topic><topic>Hepatic insulin resistance</topic><topic>high density lipoprotein</topic><topic>Hypolipidemic Agents - pharmacology</topic><topic>Inflammation</topic><topic>Injections, Intraperitoneal</topic><topic>Insulin</topic><topic>Insulin - metabolism</topic><topic>Insulin Resistance</topic><topic>interleukin-1beta</topic><topic>interleukin-6</topic><topic>lipid metabolism</topic><topic>Lipid Metabolism - drug effects</topic><topic>Liver</topic><topic>Liver - drug effects</topic><topic>Liver - metabolism</topic><topic>low density lipoprotein</topic><topic>Male</topic><topic>Mice</topic><topic>Mice, Transgenic</topic><topic>Mitochondrial Turnover - drug effects</topic><topic>Noise levels</topic><topic>noninsulin-dependent diabetes mellitus</topic><topic>Oleanolic acid</topic><topic>Oleanolic Acid - pharmacology</topic><topic>Organ Size - drug effects</topic><topic>Reactive oxygen species</topic><topic>Reactive Oxygen Species - antagonists &amp; inhibitors</topic><topic>Serums</topic><topic>triacylglycerols</topic><topic>tumor necrosis factor-alpha</topic><topic>ultrastructure</topic><topic>Weight reduction</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wang, Xin</creatorcontrib><creatorcontrib>Liu, Rui</creatorcontrib><creatorcontrib>Zhang, Wei</creatorcontrib><creatorcontrib>Zhang, Xiaodi</creatorcontrib><creatorcontrib>Liao, Nai</creatorcontrib><creatorcontrib>Wang, Zhao</creatorcontrib><creatorcontrib>Li, Wenli</creatorcontrib><creatorcontrib>Qin, Xujun</creatorcontrib><creatorcontrib>Hai, Chunxu</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Solid State and Superconductivity Abstracts</collection><collection>Technology Research Database</collection><collection>Advanced Technologies Database with Aerospace</collection><jtitle>Molecular and cellular endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wang, Xin</au><au>Liu, Rui</au><au>Zhang, Wei</au><au>Zhang, Xiaodi</au><au>Liao, Nai</au><au>Wang, Zhao</au><au>Li, Wenli</au><au>Qin, Xujun</au><au>Hai, Chunxu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects</atitle><jtitle>Molecular and cellular endocrinology</jtitle><addtitle>Mol Cell Endocrinol</addtitle><date>2013-08-25</date><risdate>2013</risdate><volume>376</volume><issue>1-2</issue><spage>70</spage><epage>80</epage><pages>70-80</pages><issn>0303-7207</issn><eissn>1872-8057</eissn><abstract>•Oleanolic acid (OA) improves hepatic insulin resistance in db/db mice.•OA inhibits mitochondrial oxidative stress via activation of Nrf2–GCLc signal.•OA suppresses hepatic lipid accumulation and inflammation. Insulin resistance is the hallmark of type 2 diabetes mellitus (T2DM), which is closely related to disorder of lipid metabolism. The study was designed to evaluate the effects of oleanolic acid (OA) on hepatic insulin resistance and underlying mechanisms in Lepdb/db obese diabetic mice. db/db Mice were administered with OA (20mg/kg/day, i.p.) for two weeks. OA reduced body weight, liver weight, and fat weight, and protected liver morphology and function. OA decreased fasting blood glucose, improved glucose and insulin tolerance, enhanced insulin signaling and inhibited gluconeogenesis. In livers, mitochondrial biogenesis, ultrastructure and function were influenced, accompanied by increased cellular and mitochondrial ROS production. OA inhibited all these changes, in which process Nrf2–GCLc mediated stabilization of mitochondrial glutathione pool may be involved. Moreover, OA decreased serum triglyceride, total cholesterol, LDL, HDL, and free fatty acids, increased serum HDL, and reduced hepatic lipid accumulation. Furthermore, inflammatory condition in db/db mice was improved by OA, as evidenced by decreased level of IL-1 β, IL-6, and TNFα in circulation and in liver. The evidence suggests that OA improves hepatic insulin resistance through inhibition of mitochondrial ROS, hypolipidemic and anti-inflammatory effects. The effectiveness of OA leads to interesting therapeutic perspectives.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>23791844</pmid><doi>10.1016/j.mce.2013.06.014</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0303-7207
ispartof Molecular and cellular endocrinology, 2013-08, Vol.376 (1-2), p.70-80
issn 0303-7207
1872-8057
language eng
recordid cdi_proquest_miscellaneous_1567091369
source MEDLINE; Elsevier ScienceDirect Journals Complete
subjects Animals
anti-inflammatory activity
Anti-Inflammatory Agents, Non-Steroidal - pharmacology
antioxidants
Antioxidants - pharmacology
biogenesis
blood glucose
Blood Glucose - metabolism
blood serum
body weight
Body Weight - drug effects
Cellular
cholesterol
Cytokines - antagonists & inhibitors
Cytokines - biosynthesis
Diabetes Mellitus, Experimental - drug therapy
Diabetes Mellitus, Experimental - metabolism
Diabetes Mellitus, Type 2 - drug therapy
Diabetes Mellitus, Type 2 - metabolism
Dyslipidemia
fasting
free fatty acids
Gluconeogenesis
Glucose
glutathione
Hepatic insulin resistance
high density lipoprotein
Hypolipidemic Agents - pharmacology
Inflammation
Injections, Intraperitoneal
Insulin
Insulin - metabolism
Insulin Resistance
interleukin-1beta
interleukin-6
lipid metabolism
Lipid Metabolism - drug effects
Liver
Liver - drug effects
Liver - metabolism
low density lipoprotein
Male
Mice
Mice, Transgenic
Mitochondrial Turnover - drug effects
Noise levels
noninsulin-dependent diabetes mellitus
Oleanolic acid
Oleanolic Acid - pharmacology
Organ Size - drug effects
Reactive oxygen species
Reactive Oxygen Species - antagonists & inhibitors
Serums
triacylglycerols
tumor necrosis factor-alpha
ultrastructure
Weight reduction
title Oleanolic acid improves hepatic insulin resistance via antioxidant, hypolipidemic and anti-inflammatory effects
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T18%3A08%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Oleanolic%20acid%20improves%20hepatic%20insulin%20resistance%20via%20antioxidant,%20hypolipidemic%20and%20anti-inflammatory%20effects&rft.jtitle=Molecular%20and%20cellular%20endocrinology&rft.au=Wang,%20Xin&rft.date=2013-08-25&rft.volume=376&rft.issue=1-2&rft.spage=70&rft.epage=80&rft.pages=70-80&rft.issn=0303-7207&rft.eissn=1872-8057&rft_id=info:doi/10.1016/j.mce.2013.06.014&rft_dat=%3Cproquest_cross%3E1567091369%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1567091369&rft_id=info:pmid/23791844&rft_els_id=S0303720713002529&rfr_iscdi=true